Sciele Pharma, Inc. (SCRX) Introduces Adrenaclick(TM) (epinephrine injection, USP) Auto-Injector for the Emergency Treatment of Anaphylaxis
1/7/2010 10:10:09 AM
ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc., a Shionogi company, today announced the U.S. availability of Adrenaclick™, a single-dose, epinephrine auto-injector for the emergency treatment for severe allergic reactions (Type I) such as anaphylaxis. Adrenaclick™ will be available as a single unit or a convenient Two-Pack. It is also available in two dosing options (0.15 mg and 0.3 mg).
comments powered by